https://www.selleckchem.com/products/fl118.html
5 months in the CCRT group (P=.655). The median PFS was 12.1 months in the NIMO-CCRT group and 13.7 months in the CCRT group (P=.968). The NIMO-CCRT group had a significantly lower risk of brain metastasis, with adjusted subdistribution hazard ratio of 0.099 (95% confidence interval, 0.012-0.81; P=.031). The incidence of grade ≥3 pneumonitis (P=.894) and esophagitis (P=.974) was similar between the 2 arms. There was no grade 2 or higher skin toxicity in NIMO-CCRT group. The coincident application of nimotuzumab with CCRT was well tolerate
Like
Comment
Share
